Cyclo Therapeutics Statistics
Total Valuation
CYTH has a market cap or net worth of $34.62 million. The enterprise value is $32.29 million.
| Market Cap | 34.62M |
| Enterprise Value | 32.29M |
Important Dates
The next estimated earnings date is Monday, August 12, 2024, before market open.
| Earnings Date | Aug 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CYTH has 28.61 million shares outstanding. The number of shares has increased by 159.78% in one year.
| Shares Outstanding | 28.61M |
| Shares Change (YoY) | +159.78% |
| Shares Change (QoQ) | +75.05% |
| Owned by Insiders (%) | 39.91% |
| Owned by Institutions (%) | 12.81% |
| Float | 15.88M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 30.74 |
| Forward PS | 26.06 |
| PB Ratio | 56.76 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 28.67 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.01, with a Debt / Equity ratio of 1.09.
| Current Ratio | 1.01 |
| Quick Ratio | 0.47 |
| Debt / Equity | 1.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -2,741.60% and return on invested capital (ROIC) is -1,581.39%.
| Return on Equity (ROE) | -2,741.60% |
| Return on Assets (ROA) | -253.10% |
| Return on Capital (ROIC) | -1,581.39% |
| Revenue Per Employee | $140,806 |
| Profits Per Employee | -$2.42M |
| Employee Count | 8 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 0.35 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -19.33% in the last 52 weeks. The beta is -0.33, so CYTH's price volatility has been lower than the market average.
| Beta (5Y) | -0.33 |
| 52-Week Price Change | -19.33% |
| 50-Day Moving Average | 1.29 |
| 200-Day Moving Average | 1.40 |
| Relative Strength Index (RSI) | 45.15 |
| Average Volume (20 Days) | 27,367 |
Short Selling Information
The latest short interest is 29,113, so 0.10% of the outstanding shares have been sold short.
| Short Interest | 29,113 |
| Short Previous Month | 11,707 |
| Short % of Shares Out | 0.10% |
| Short % of Float | 0.18% |
| Short Ratio (days to cover) | 1.08 |
Income Statement
In the last 12 months, CYTH had revenue of $1.13 million and -$19.39 million in losses. Loss per share was -$1.00.
| Revenue | 1.13M |
| Gross Profit | 1.04M |
| Operating Income | -20.16M |
| Pretax Income | -19.39M |
| Net Income | -19.39M |
| EBITDA | -19.38M |
| EBIT | -19.39M |
| Loss Per Share | -$1.00 |
Balance Sheet
The company has $3.00 million in cash and $665,063 in debt, giving a net cash position of $2.33 million or $0.08 per share.
| Cash & Cash Equivalents | 3.00M |
| Total Debt | 665,063 |
| Net Cash | 2.33M |
| Net Cash Per Share | $0.08 |
| Equity (Book Value) | 610,014 |
| Book Value Per Share | 0.02 |
| Working Capital | 33,703 |
Cash Flow
In the last 12 months, operating cash flow was -$18.00 million and capital expenditures -$2,420, giving a free cash flow of -$18.00 million.
| Operating Cash Flow | -18.00M |
| Capital Expenditures | -2,420 |
| Free Cash Flow | -18.00M |
| FCF Per Share | -$0.63 |
Margins
Gross margin is 92.37%, with operating and profit margins of -1,790.06% and -1,721.64%.
| Gross Margin | 92.37% |
| Operating Margin | -1,790.06% |
| Pretax Margin | -1,721.64% |
| Profit Margin | -1,721.64% |
| EBITDA Margin | -1,720.16% |
| EBIT Margin | -1,721.64% |
| FCF Margin | -1,597.89% |
Dividends & Yields
CYTH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -159.78% |
| Shareholder Yield | -159.78% |
| Earnings Yield | -56.01% |
| FCF Yield | -51.99% |
Analyst Forecast
The average price target for CYTH is $3.20, which is 164.46% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.20 |
| Price Target Difference | 164.46% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on December 9, 2020. It was a reverse split with a ratio of 1:100.
| Last Split Date | Dec 9, 2020 |
| Split Type | Reverse |
| Split Ratio | 1:100 |
Scores
CYTH has an Altman Z-Score of -22.84 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -22.84 |
| Piotroski F-Score | 4 |